Newswire (Published: Tuesday, February 7, 2017, Received: Thursday, February 2, 2017, 2:45:05 PM CST)

Word Count: 473

New Findings on Prostate Cancer Discussed by Researchers at Duke University Medical Center (Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer)

By a News Reporter-Staff News Editor at Cancer Weekly -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting out of Durham, North Carolina, by NewsRx editors, research stated, "Treatment with androgen-targeted therapies can induce upregulation of epithelial plasticity pathways. Epithelial plasticity is known to be important for metastatic dissemination and therapeutic resistance."

Our news journalists obtained a quote from the research from Duke University Medical Center, "The goal of this study is to elucidate the functional consequence of induced epithelial plasticity on AR regulation during disease progression to identify factors important for treatment-resistant and metastatic prostate cancer. We pinpoint the epithelial plasticity transcription factor, Snail, at the nexus of enzalutamide resistance and prostate cancer metastasis both in preclinical models of prostate cancer and in patients. In patients, Snail expression is associated with Gleason 9-10 high-risk disease and is strongly overexpressed in metastases as compared to localized prostate cancer. Snail expression is also elevated in enzalutamide-resistant prostate cancer cells compared to enzalutamide-sensitive cells, and downregulation of Snail re-sensitizes enzalutamide-resistant cells to enzalutamide. While activation of Snail increases migration and invasion, it is also capable of promoting enzalutamide resistance in enzalutamide-sensitive cells. This Snail-mediated enzalutamide resistance is a consequence of increased full-length AR and AR-V7 expression and nuclear localization. Downregulation of either full-length AR or AR-V7 re-sensitizes cells to enzalutamide in the presence of Snail, thus connecting Snail-induced enzalutamide resistance directly to AR biology. Finally, we demonstrate that Snail is capable of mediating-resistance through AR even in the absence of AR-V7."

According to the news editors, the research concluded: "These findings imply that increased Snail expression during progression to metastatic disease may prime cells for resistance to AR-targeted therapies by promoting AR activity in prostate cancer."

For more information on this research see: Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget, 2016;7(31):50507-50521 (see also Oncology - Prostate Cancer).

Our news journalists report that additional information may be obtained by contacting K.E. Ware, Dept. of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, United States. Additional authors for this research include J.A. Somarelli, D. Schaeffer, J. Li, T. Zhang, S. Park, S.R. Patierno, J. Freedman, W.C. Foo, M.A. Garcia-Blanco and A.J Armstrong.

Keywords for this news article include: Durham, Genetics, Oncology, United States, North Carolina, Prostate Cancer, Steroid Receptors, Androgen Receptors, Prostatic Neoplasms, DNA Binding Proteins, Transcription Factors, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


      Healthcare Facilities


Central America
North America
United States
North Carolina


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research